Mirum Pharmaceuticals, Inc. director Saira Ramasastry filed a Form 4 on November 17, 2026, disclosing the exercise of 2,000 stock options and the same-day sale of 2,000 shares of common stock on November 16, 2026, pursuant to a Rule 10b5-1 plan.
Key Highlights
- Option exercise: Ramasastry exercised 2,000 stock options (transaction code M) on November 16, 2026, at an exercise price of $28.97 per share.
- Share sale: 2,000 shares of common stock were sold on November 16, 2026, at a price of $92.28 per share under a Rule 10b5-1 plan.
- 10b5-1 plan: According to the filing, the sale was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 10, 2026.
- Remaining options: Following the transactions, Ramasastry beneficially owns 15,000 stock options (direct), with an exercise price of $28.97 and an expiration date of June 11, 2033.
- Post-transaction common stock ownership: Ramasastry's direct beneficial ownership of common stock following the reported transactions is 0 shares.
- Fully vested options: The filing notes that the stock option exercised is fully vested.
Mirum Pharmaceuticals Director Ramasastry's Option Exercise and Stock Sale Details
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 17, 2026, Saira Ramasastry, a director of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), reported two transactions in the company's common stock, both occurring on November 16, 2026. The first was the exercise of 2,000 stock options at an exercise price of $28.97 per share (transaction code M). The filing notes the exercised option is fully vested and carries an expiration date of June 11, 2033.
The second transaction was the disposition of the 2,000 shares of common stock acquired through that exercise, sold at a price of $92.28 per share (transaction code S). The filing states the sale "occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on August 10, 2026." Following both transactions, Ramasastry's direct beneficial ownership of Mirum common stock is reported as 0 shares.
In Table II of the filing, Ramasastry's remaining derivative securities position is listed as 15,000 stock options (direct ownership) with the same exercise price of $28.97 and the same June 11, 2033 expiration date. The form was signed by Judit Ryvkin as Attorney-in-Fact on November 17, 2026, and the filing indicates a check was made indicating the sale was made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).
What Was Disclosed
Mirum Pharmaceuticals director Saira Ramasastry disclosed the exercise of 2,000 fully vested stock options at $28.97 and the sale of 2,000 common shares at $92.28 on November 16, 2026, under a pre-established Rule 10b5-1 plan. Ramasastry retains 15,000 stock options directly.




Please wait processing your request...